Abstract Number: 0535 • ACR Convergence 2022
Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…Abstract Number: 0840 • ACR Convergence 2022
Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy
Background/Purpose: Recent literature suggests that rheumatic disease patients hold most immunosuppressive (IS) medications before and after joint replacement surgery, to prevent infections and other complications.…Abstract Number: 1593 • ACR Convergence 2022
Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample
Background/Purpose: Infection is the leading cause of hospitalization and mortality in SLE. Care of young adults (YA) with SLE is particularly challenging, with higher mortality…Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…Abstract Number: 0252 • ACR Convergence 2021
Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Fever is the most common presentation of systemic juvenile idiopathic arthritis (SJIA) and it is difficult to predict whether the fever is due to…Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…Abstract Number: 0337 • ACR Convergence 2021
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Background/Purpose: Infection is the leading cause of mortality and one of the most common causes of hospitalization in patients with systemic lupus erythematosus (SLE). Pneumocystis…Abstract Number: 1027 • ACR Convergence 2021
Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients
Background/Purpose: Background: Patients with rheumatologic immune-mediated diseases (R-IMID) with Latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at an increased risk of active tuberculosis…Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…Abstract Number: 0427 • ACR Convergence 2021
Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study
Background/Purpose: Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a group of multisystem inflammatory diseases of the small blood vessels. Infections are serious complications in AAV…Abstract Number: 1094 • ACR Convergence 2021
Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis
Background/Purpose: To compare the laboratory characteristics of patients who had rheumatic diseases and presented with extremely elevated ESR (≥100 mm/h) and had either disease flare-up…Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…Abstract Number: 0429 • ACR Convergence 2021
Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis
Background/Purpose: Despite improvements, patients with ANCA-associated vasculitis (AAV) have a higher risk of death than the general population. Contemporary treatment is associated with high remission…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 32
- Next Page »